1-11 of 11
Cem Elbi
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 4816: Anetumab ravtansine has monotherapy efficacy in mesothelin positive patient-derived NSCLC tumor models and in a syngeneic tumor model in immunocompetent mice

Anette Sommer, Pascale Lejeune, Sabine Hoff, Annette O. Walter, Sandra Berndt, Lars Roese, Andreas Schlicker, Michael J. Wick, Cem Elbi, Dominik Mumberg, Christoph Schatz
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): 4816.
https://doi.org/10.1158/1538-7445.AM2019-4816
Published: 01 July 2019
View article titled, Abstract 4816: Anetumab ravtansine has monotherapy efficacy in mesothelin positive patient-derived NSCLC tumor models and in a syngeneic tumor model in immunocompetent mice
Journal Articles

Abstract 1780: Anetumab ravtansine has single-agent activity in mesothelin-expressing human ovarian cancer models and potentiates the activity of chemotherapeutics and targeted agents

Christoph A. Schatz, Maria Quanz, Urs B. Hagemann, Sabine Zitzmann-Kolbe, Beatrix Stelte-Ludwig, Sven Golfier, Charlotte Kopitz, Cem Elbi, Karl Ziegelbauer, Dominik Mumberg
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 1780.
https://doi.org/10.1158/1538-7445.AM2018-1780
Published: 01 July 2018
View article titled, Abstract 1780: Anetumab ravtansine has single-agent activity in mesothelin-expressing human ovarian cancer models and potentiates the activity of chemotherapeutics and targeted agents
Journal Articles

Abstract CT083: A pivotal randomized phase II study of anetumab ravtansine or vinorelbine in patients with advanced or metastatic pleural mesothelioma after progression on platinum/pemetrexed-based chemotherapy (NCT02610140)

Raffit Hassan, John J. Nemunaitis, Jan P. van Meerbeeck, Ross Jennens, George R. Blumenschein, Jr, Dean A. Fennell, Hedy L. Kindler, Silvia Novello, Cem Elbi, Annette Walter, Danila Serpico, Emma Fountain, Sandra Vingerhoedt, Christine Brown, Jonathan Siegel, Barrett H. Childs
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): CT083.
https://doi.org/10.1158/1538-7445.AM2016-CT083
Published: 15 July 2016
View article titled, Abstract CT083: A pivotal randomized phase II study of anetumab ravtansine or vinorelbine in patients with advanced or metastatic pleural mesothelioma after progression on platinum/pemetrexed-based chemotherapy (NCT02610140)
Journal Articles

Abstract 3090: Novel Mps1 kinase inhibitors with potent anti-tumor activity

Antje Margret Wengner, Gerhard Siemeister, Marcus Koppitz, Volker Schulze, Dirk Kosemund, Ulrich Klar, Detlef Stoeckigt, Roland Neuhaus, Philip Lienau, Benjamin Bader, Stefan Prechtl, Olaf Doehr, Marian Raschke, Oliver von Ahsen, Cem Elbi, Ingmar Bruns, Martin Michels, Bertolt Kreft, Franz von Nussbaum, Michael Brands, Dominik Mumberg, Karl Ziegelbauer
Journal: Cancer Research
Cancer Res (2015) 75 (15_Supplement): 3090.
https://doi.org/10.1158/1538-7445.AM2015-3090
Published: 01 August 2015
View article titled, Abstract 3090: Novel Mps1 kinase inhibitors with potent anti-tumor activity
Journal Articles

Abstract 685: PARP inhibitor MK-4827 is synthetic lethal for tumors with homologous recombination defects associated with ATM-deficiency, PTEN-deletion and microsatellite instability (MSI)

Giuseppe Roscilli, Gerald Gavory, Stefania Lamartina, Emanuele Marra, Brian Dolinski, Sybil Williams, Cem Elbi, Philip Jones, Christopher L. Carpenter, Carlo Toniatti
Journal: Cancer Research
Cancer Res (2010) 70 (8_Supplement): 685.
https://doi.org/10.1158/1538-7445.AM10-685
Published: 15 April 2010
View article titled, Abstract 685: PARP inhibitor MK-4827 is synthetic lethal for tumors with homologous recombination defects associated with ATM-deficiency, PTEN-deletion and microsatellite instability (MSI)
Journal Articles

High-content small-molecule and siRNA screening in oncology drug discovery.

Julie Gorenstein, Ben Zack, Joseph Marszalek, Suzanne Rodday, Ansu Bagchi, Sai Subramanian, Pamela Carroll, Cem Elbi
Journal: Cancer Research
Cancer Res (2008) 68 (9_Supplement): 5168.
Published: 01 May 2008
View article titled, High-content small-molecule and siRNA screening in oncology drug discovery.
Journal Articles

FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival

Bart Lutterbach, Kaiko Kunii, Lenora Davis, Harold Hatch, Julie Gorenstein, Masakazu Yashiro, Victoria Richon, Nancy Kohl, Cem Elbi, Wei Lu, Bo-Sheng Pan
Journal: Cancer Research
Cancer Res (2008) 68 (9_Supplement): 4874.
Published: 01 May 2008
View article titled, <em>FGFR2</em>-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival
Journal Articles

Attenuation of Notch signaling pathway by gamma-secretase inhibitor exerts antitumor effects in T-ALL through apoptotic mechanisms.

Jennifer Tammam, Christopher Ware, Clay Efferson, Xianlu Qu, Hellen Kim, Julie Gorenstein, Minilik Angagaw, Candia Kenific, Kaiko Kunii, Jun Zhao, Cem Elbi, Linda Bristow, John Reilly, George Nikov, Nancy Kohl, Peter Strack, Pradip Majumder
Journal: Cancer Research
Cancer Res (2008) 68 (9_Supplement): LB-23.
Published: 01 May 2008
View article titled, Attenuation of Notch signaling pathway by gamma-secretase inhibitor exerts antitumor effects in T-ALL through apoptotic mechanisms.
Journal Articles

FGFR2-Amplified Gastric Cancer Cell Lines Require FGFR2 and Erbb3 Signaling for Growth and Survival

Kaiko Kunii, Lenora Davis, Julie Gorenstein, Harold Hatch, Masakazu Yashiro, Alessandra Di Bacco, Cem Elbi, Bart Lutterbach
Journal: Cancer Research
Cancer Res (2008) 68 (7): 2340–2348.
https://doi.org/10.1158/0008-5472.CAN-07-5229
Published: 01 April 2008
View article titled, <em>FGFR2</em>-Amplified Gastric Cancer Cell Lines Require FGFR2 and Erbb3 Signaling for Growth and Survival
Open the PDF for <em>FGFR2</em>-Amplified Gastric Cancer Cell Lines Require FGFR2 and Erbb3 Signaling for Growth and Survival in another window
Includes: Supplementary data
Journal Articles

Kallikrein 4 is a Predominantly Nuclear Protein and Is Overexpressed in Prostate Cancer

Zhijun Xi, Tove Irene Klokk, Kemal Korkmaz, Piotr Kurys, Cem Elbi, Bjørn Risberg, Håvard Danielsen, Massimo Loda, Fahri Saatcioglu
Journal: Cancer Research
Cancer Res (2004) 64 (7): 2365–2370.
https://doi.org/10.1158/0008-5472.CAN-03-2025
Published: 01 April 2004
View article titled, Kallikrein 4 is a Predominantly Nuclear Protein and Is Overexpressed in Prostate Cancer
Open the PDF for Kallikrein 4 is a Predominantly Nuclear Protein and Is Overexpressed in Prostate Cancer in another window
Journal Articles

Kallikrein 4 is a predominantly nuclear protein and is over-expressed in prostate cancer

Zhijun Xi, Tove I. Klokk, Kemal Korkmaz, Piotr Kurys, Cem Elbi, Bjørn Risberg, Håvard Danielsen, Massimo Loda, Fahri Saatcioglu
Journal: Cancer Research
Cancer Res (2004) 64 (7_Supplement): 244.
Published: 01 April 2004
View article titled, Kallikrein 4 is a predominantly nuclear protein and is over-expressed in prostate cancer